10/25, 2:40 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Moderna

Moderna: Vaccine data in 6-11 years olds positive

Moderna Inc. announced on Monday that the results from the Phase 2/3 study of its COVID-19 vaccine in children aged between 6 and 11 years came back positive.

"We are encouraged by the immunogenicity and safety profile of mRNA-1273 in children aged 6 to under 12 years and are pleased that the study met its primary immunogenicity endpoints. We look forward to filing with regulators globally and remain committed to doing our part to help end the COVID-19 pandemic with a vaccine for adults and children of all ages," CEO Stephane Bancel noted.

Moderna said that the two-dose vaccine was well tolerated and effective among trialed children, and that the company would soon submit the results to the United States Food and Drug Administration and other health regulatory agencies worldwide.

Breaking the News / ND